We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Sunstone Hotel Investors
SHO
$2.04B
| $35.5M | 0.05% |
3,100,000
| – | – |
|
352
Nabors Industries
NBR
$1.38B
| $35.3M | 0.05% |
420,000
-320,000
| -43% | -$29.8M |
|
353
Northrop Grumman
NOC
$73.2B
| $35.3M | 0.05% |
69,233
-31,139
| -31% | -$18M |
|
354
MSCI
MSCI
$40.3B
| $34.9M | 0.05% |
62,400
-2,400
| -4% | -$1.4M |
|
|
GRMN
355
Garmin
GRMN
$52.5B
| $34.7M | 0.05% |
146,070
-400
| -0.3% | -$97.3K |
|
356
Interactive Brokers
IBKR
$40.9B
| $34.6M | 0.05% |
397,000
-2,000
| -0.5% | -$166K |
|
357
Core Scientific
CORZ
$5.81B
| $34.4M | 0.05% |
1,343,135
-250,000
| -16% | -$5.89M |
|
358
Williams-Sonoma
WSM
$26.8B
| $34.2M | 0.05% |
146,900
+78,400
| +114% | +$15.5M |
|
359
DNOW Inc
DNOW
$2.92B
| $34.2M | 0.05% |
+2,635,000
| New | +$34.2M |
|
360
Amylyx Pharmaceuticals
AMLX
$3.61B
| $34.1M | 0.05% |
1,900,000
-1,660,764
| -47% | -$25.7M |
|
361
Commercial Metals
CMC
$7.63B
| $34.1M | 0.05% |
543,527
+293,527
| +117% | +$20.6M |
|
|
ORKA
362
Oruka Therapeutics
ORKA
$6.06B
| $33.8M | 0.05% |
355,003
+164,973
| +87% | +$11M |
|
363
Cheniere Energy
LNG
$57B
| $33.5M | 0.05% |
+140,000
| New | +$34.9M |
|
364
Applied Industrial Technologies
AIT
$11.9B
| $33.4M | 0.05% |
98,854
-78,156
| -44% | -$24M |
|
|
APGE
365
DELISTED
Apogee Therapeutics
APGE
| $33.2M | 0.05% |
250,000
| – | – |
|
366
Ford
F
$53.6B
| $33M | 0.05% |
+2,377,200
| New | +$32.1M |
|
367
Relmada Therapeutics
RLMD
$436M
| $33M | 0.05% |
4,763,158
| – | – |
|
368
Aura Biosciences
AURA
$747M
| $32.9M | 0.05% |
4,640,000
-241,125
| -5% | -$1.73M |
|
369
Emcor
EME
$33.3B
| $32.9M | 0.05% |
39,600
-500
| -1% | -$423K |
|
370
Archer Daniels Midland
ADM
$41.7B
| $32.8M | 0.05% |
429,592
-250,900
| -37% | -$19.1M |
|
371
Carnival Corporation Ltd
CCL
$31.1B
| $32.8M | 0.05% |
1,146,500
+319,200
| +39% | +$8.72M |
|
|
CLYM
372
Climb Bio
CLYM
$864M
| $32.7M | 0.05% |
+2,506,000
| New | +$25.9M |
|
373
Relay Therapeutics
RLAY
$4.09B
| $32.6M | 0.05% |
1,740,000
-850,000
| -33% | -$12.3M |
|
374
Financial Institutions
FISI
$804M
| $32.5M | 0.05% |
834,969
-113,472
| -12% | -$4.03M |
|
375
Avalo Therapeutics
AVTX
$977M
| $32M | 0.04% |
1,729,000
+875,000
| +102% | +$13.8M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.